Bladder EpiCheck® - Reduce invasive procedures with an accurate urine test.
Bladder EpiCheck® is a non-invasive urine assay using a panel of 15 DNA methylation biomarkers to assess the presence of bladder cancer in patients, who have history of bladder cancer. Bladder EpiCheck® is designed for better monitoring of non-muscle invasive bladder cancer and reducing the number of follow-up cystoscopies.
The test comprises of two platforms: the biochemical tool utilizes real-time PCR technique and the software tool provides an automated objective analysis of the PCR results. Bladder EpiCheck® has excellent non-invasive tumour detection results for high-grade tumours. The test can be used as a rule-out test for high-grade disease with a negative predictive value of 99 %. When bladder cancer is detected with a urine sample, the number of expensive and invasive follow-up cystoscopies can be reduced.
Bladder EpiCheck® provides you with
- 99 % Negative Predictive Value
- Objective and operator independent test results with excellent high-grade sensitivity and specificity (92 % and 88 %)
- Simple test result interpretation (pos/neg and EpiScore from 0-100)
- Potential reduction in follow-up cystoscopies resulting in reduced patient and financial burden
|Use||For in vitro diagnostic use|
|Time to result||1 day|
|Additionally needed||Validated real-time PCR instruments include Applied Biosystems 7500 Fast Dx real time PCR instrument and Rotor-Gene Q Plex-5 instrument. Bladder EpiCheck® software available from the manufacturer’s website (https://www.nucleix.com/downloads/)|
More information about Bladder EpiCheck® can be found from Nucleix Ltd website: https://www.nucleix.com/bladder-epicheck/